白细胞介素-4/-13轴及其阻断在特应性皮炎治疗中的应用
The IL-4/-13 Axis and Its Blocking in the Treatment of Atopic Dermatitis.
作者信息
Pappa Georgia, Sgouros Dimitrios, Theodoropoulos Konstantinos, Kanelleas Antonios, Bozi Evangelia, Gregoriou Stamatios, Krasagakis Konstantinos, Katoulis Alexander C
机构信息
2nd Department of Dermatology and Venereology, "Attikon" General University Hospital, Medical School, National and Kapodistrian University of Athens, 12462 Athens, Greece.
1st Department of Dermatology and Venereology, "Andreas Suggros" Hospital, Medical School, National and Kapodistrian University of Athens, 16121 Athens, Greece.
出版信息
J Clin Med. 2022 Sep 24;11(19):5633. doi: 10.3390/jcm11195633.
Abstract
Atopic dermatitis (AD) is a common inflammatory skin disease with a complex pathophysiology, intertwining immune dysregulation, epidermal barrier dysfunction, IgE sensitization, environmental factors and genetic predisposition. It has been recently identified that interleukins -4 and -13 play crucial roles in the type-2-driven inflammation that characterizes AD, contributing to its symptomatology. Novel therapeutic approaches that target Th2 cytokines and their respective pathways have been developed, aiming to optimize the treatment of AD.
摘要
特应性皮炎（AD）是一种常见的炎症性皮肤病，其病理生理学复杂，涉及免疫失调、表皮屏障功能障碍、IgE致敏、环境因素和遗传易感性。最近发现，白细胞介素-4和-13在以2型为主导的炎症中起关键作用，这种炎症是AD的特征，导致其症状。针对Th2细胞因子及其各自途径的新型治疗方法已经开发出来，旨在优化AD的治疗。
相似文献
1
The IL-4/-13 Axis and Its Blocking in the Treatment of Atopic Dermatitis.白细胞介素-4/-13轴及其阻断在特应性皮炎治疗中的应用
J Clin Med. 2022 Sep 24;11(19):5633. doi: 10.3390/jcm11195633.
2
The IL-4, IL-13 and IL-31 pathways in atopic dermatitis.特应性皮炎中的 IL-4、IL-13 和 IL-31 通路。
Expert Rev Clin Immunol. 2021 Aug;17(8):835-852. doi: 10.1080/1744666X.2021.1940962. Epub 2021 Jul 21.
3
Therapeutic New Era for Atopic Dermatitis: Part 1. Biologics.特应性皮炎的治疗新时代：第1部分。生物制剂。
Ann Dermatol. 2021 Feb;33(1):1-10. doi: 10.5021/ad.2021.33.1.1. Epub 2020 Dec 30.
4
Atopic dermatitis and cytokines: recent patents in immunoregulatory and therapeutic implications of cytokines in atopic dermatitis--part I: cytokines in atopic dermatitis.特应性皮炎与细胞因子：细胞因子在特应性皮炎中的免疫调节及治疗意义的近期专利——第一部分：特应性皮炎中的细胞因子
Recent Pat Inflamm Allergy Drug Discov. 2012 Sep;6(3):222-47. doi: 10.2174/187221312802652820.
5
Intrinsic atopic dermatitis shows similar TH2 and higher TH17 immune activation compared with extrinsic atopic dermatitis.特应性皮炎的内在型与外在型相比，具有相似的 TH2 和更高的 TH17 免疫激活。
J Allergy Clin Immunol. 2013 Aug;132(2):361-70. doi: 10.1016/j.jaci.2013.04.046. Epub 2013 Jun 15.
6
Herpes Simplex Virus 1 Can Bypass Impaired Epidermal Barriers upon Infection of Skin from Atopic Dermatitis Patients.单纯疱疹病毒 1 可在感染特应性皮炎患者皮肤时绕过受损的表皮屏障。
J Virol. 2022 Sep 14;96(17):e0086422. doi: 10.1128/jvi.00864-22. Epub 2022 Aug 15.
7
Biologic Therapy for Atopic Dermatitis: Moving Beyond the Practice Parameter and Guidelines.特应性皮炎的生物治疗：超越实践参数和指南。
J Allergy Clin Immunol Pract. 2017 Nov-Dec;5(6):1477-1487. doi: 10.1016/j.jaip.2017.08.031.
8
Multiple Roles for Cytokines in Atopic Dermatitis: From Pathogenic Mediators to Endotype-Specific Biomarkers to Therapeutic Targets.细胞因子在特应性皮炎中的多重作用：从致病介质到表型特异性生物标志物再到治疗靶点。
Int J Mol Sci. 2022 Feb 28;23(5):2684. doi: 10.3390/ijms23052684.
9
Etiopathogenesis of atopic dermatitis--an overview.特应性皮炎的病因发病机制——综述
Acta Dermatovenerol Croat. 2005;13(1):54-62.
10
The role of interleukin-17 in mouse models of atopic dermatitis and contact dermatitis.白细胞介素-17在特应性皮炎和接触性皮炎小鼠模型中的作用。
Clin Exp Dermatol. 2015 Aug;40(6):665-71. doi: 10.1111/ced.12567. Epub 2015 Feb 16.
引用本文的文献
1
Symbiotic bacteria-mediated imbalance and repair of immune homeostasis: exploring novel mechanisms of microbiome-host interactions in atopic dermatitis.共生细菌介导的免疫稳态失衡与修复：探索特应性皮炎中微生物群 - 宿主相互作用的新机制
Front Immunol. 2025 Jul 23;16:1649857. doi: 10.3389/fimmu.2025.1649857. eCollection 2025.
2
Partially hydrolyzed guar gum ingestion suppresses atopic dermatitis-like symptoms through prebiotic effect in mice.摄入部分水解瓜尔胶通过对小鼠的益生元效应抑制特应性皮炎样症状。
J Clin Biochem Nutr. 2025 May;76(3):280-288. doi: 10.3164/jcbn.24-219. Epub 2025 Feb 6.
3
Construction and Evaluation of an Artificial Intelligence Assistant Decision-Making System Focused on the Treat-to-Target Framework and Full Process Management for Atopic Dermatitis: Study Protocol for a Randomized Controlled Trial.聚焦特应性皮炎达标治疗框架及全程管理的人工智能辅助决策系统的构建与评估：一项随机对照试验的研究方案
J Clin Med. 2025 Apr 27;14(9):3015. doi: 10.3390/jcm14093015.
4
Real-World Effectiveness and Safety of Upadacitinib and Abrocitinib in Moderate-to-Severe Atopic Dermatitis: A 52-Week Retrospective Study.乌帕替尼和阿布昔替尼治疗中度至重度特应性皮炎的真实世界有效性和安全性：一项52周的回顾性研究。
J Clin Med. 2025 Apr 24;14(9):2953. doi: 10.3390/jcm14092953.
5
T cell immunophenotypes and IgE responses in patients with moderate-to-severe atopic dermatitis receiving dupilumab.接受度普利尤单抗治疗的中重度特应性皮炎患者的T细胞免疫表型和IgE反应
Clin Transl Allergy. 2025 May;15(5):e70062. doi: 10.1002/clt2.70062.
6
Cure for the itch: current clinical standards and therapies in allergic eczema.瘙痒症的治疗：过敏性湿疹的当前临床标准与疗法
Front Allergy. 2025 Apr 3;6:1569292. doi: 10.3389/falgy.2025.1569292. eCollection 2025.
7
Efficacy and Safety of 611 in Chinese Adults with Moderate-to-Severe Atopic Dermatitis: Results from a Phase II Trial.611对中国中重度特应性皮炎成人患者的疗效与安全性：一项II期试验的结果
Dermatol Ther (Heidelb). 2025 Apr;15(4):857-867. doi: 10.1007/s13555-025-01368-4. Epub 2025 Mar 9.
8
The primary mechanisms underlying atopic dermatitis.特应性皮炎的主要潜在机制。
Tunis Med. 2025 Jan 5;103(1):65-72. doi: 10.62438/tunismed.v103i1.5220.
9
Topical Anti-Inflammatory Effects of Quercetin Glycosides on Atopic Dermatitis-Like Lesions: Influence of the Glycone Type on Efficacy and Skin Absorption.槲皮素糖苷对特应性皮炎样皮损的局部抗炎作用：糖苷类型对疗效和皮肤吸收的影响。
Inflammation. 2025 Jan 14. doi: 10.1007/s10753-025-02236-1.
10
Quercetin as a therapeutic agent for skin problems: a systematic review and meta-analysis on antioxidant effects, oxidative stress, inflammation, wound healing, hyperpigmentation, aging, and skin cancer.槲皮素作为皮肤问题的治疗剂：关于抗氧化作用、氧化应激、炎症、伤口愈合、色素沉着、衰老和皮肤癌的系统评价与荟萃分析
Naunyn Schmiedebergs Arch Pharmacol. 2025 May;398(5):5011-5055. doi: 10.1007/s00210-024-03722-3. Epub 2024 Dec 30.
本文引用的文献
1
Dupilumab-induced hypereosinophilia: review of the literature and algorithm proposal for clinical management.度匹鲁单抗引起的嗜酸性粒细胞增多症：文献复习及临床管理算法建议。
Expert Rev Respir Med. 2022 Jul;16(7):713-721. doi: 10.1080/17476348.2022.2090342. Epub 2022 Jun 23.
2
Managing Atopic Dermatitis with Lebrikizumab - The Evidence to Date.使用乌帕替尼治疗特应性皮炎——迄今的证据
Clin Cosmet Investig Dermatol. 2022 Jun 8;15:1065-1072. doi: 10.2147/CCID.S295672. eCollection 2022.
3
Real-World Effectiveness of Dupilumab in Atopic Dermatitis Patients: Analysis of an Electronic Medical Records Dataset.度普利尤单抗在特应性皮炎患者中的真实世界有效性：电子病历数据集分析
Dermatol Ther (Heidelb). 2022 Jun;12(6):1337-1350. doi: 10.1007/s13555-022-00731-z. Epub 2022 May 11.
4
Conjunctivitis in adult patients with moderate-to-severe atopic dermatitis: results from five tralokinumab clinical trials.成人中重度特应性皮炎患者的结膜炎：五项特利鲁单抗临床试验结果。
Br J Dermatol. 2022 Mar;186(3):453-465. doi: 10.1111/bjd.20810. Epub 2021 Nov 28.
5
Management of inadequate response and adverse effects to dupilumab in atopic dermatitis.特应性皮炎中对度普利尤单抗反应不足及不良反应的管理。
J Am Acad Dermatol. 2022 Mar;86(3):628-636. doi: 10.1016/j.jaad.2021.06.017. Epub 2021 Jun 11.
6
The IL-4, IL-13 and IL-31 pathways in atopic dermatitis.特应性皮炎中的 IL-4、IL-13 和 IL-31 通路。
Expert Rev Clin Immunol. 2021 Aug;17(8):835-852. doi: 10.1080/1744666X.2021.1940962. Epub 2021 Jul 21.
7
Dupilumab suppresses type 2 inflammatory biomarkers across multiple atopic, allergic diseases.度普利尤单抗可抑制多种特应性、过敏性疾病的 2 型炎症生物标志物。
Clin Exp Allergy. 2021 Jul;51(7):915-931. doi: 10.1111/cea.13954. Epub 2021 Jun 26.
8
Dupilumab Improves Asthma and Sinonasal Outcomes in Adults with Moderate to Severe Atopic Dermatitis.度普利尤单抗可改善中重度特应性皮炎成人的哮喘和鼻-鼻窦结局。
J Allergy Clin Immunol Pract. 2021 Mar;9(3):1212-1223.e6. doi: 10.1016/j.jaip.2020.12.059. Epub 2021 Jan 13.
9
Targeting IL-4 for the Treatment of Atopic Dermatitis.以白细胞介素-4为靶点治疗特应性皮炎
Immunotargets Ther. 2020 Sep 29;9:151-156. doi: 10.2147/ITT.S260370. eCollection 2020.
10
Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trial.特利鲁单抗联合局部皮质类固醇治疗中重度特应性皮炎：来自双盲、随机、多中心、安慰剂对照 III 期 ECZTRA 3 试验的结果。
Br J Dermatol. 2021 Mar;184(3):450-463. doi: 10.1111/bjd.19573. Epub 2021 Feb 22.
Zotero 插件